other material
confidence high
sentiment positive
materiality 0.70
Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne
Dermata Therapeutics, Inc.
- IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.
- Inflammatory lesion count mean change: -11.4 XYNGARI vs -8.6 placebo (p<0.001).
- Non-inflammatory lesion count mean change: -12.4 XYNGARI vs -8.8 placebo (p<0.001).
- Data support earlier positive week 12 topline results for all primary endpoints.